NEWS

Kizoo leads financing round in Reservoir Neuroscience to restore health to the aging brain

Aaron Friedman and Vlad Senatorov

Reservoir Neuroscience announced today the completion of a $4M financing round to support the development of new therapies for age-related neurodegeneration. Reservoir will use the funds to develop its novel class of drug compounds designed to restore health to the brain’s blood vessels to rejuvenate the aging brain. The round was led by Kizoo Technology Capital, a leading rejuvenation biotech investor focused on startups reversing age-related damage at the cellular and molecular level, with additional participation from previous investors R42 Fund and Healthspan Ventures.

Read More

Save the date: Rejuvenation Startup Summit: May, 10-11 in Berlin

Rejuvenation Startup Summit 2024

The Forever Healthy Foundation is pleased to announce the second edition of the Rejuvenation Startup Summit, following the inaugural Rejuvenation Startup Summit in 2022 with more than 400 participants from over 30 countries. It will take place on 10-11 May 2024 in Berlin.

The Rejuvenation Startup Summit is the world’s largest in-person gathering of longevity startups. It brings together startups, members of the longevity venture capital / investor ecosystem, and researchers interested in starting or joining a startup – all with the goal of accelerating the development of the rejuvenation biotech industry.

Read More

Kizoo portfolio company and Harvard spin-off CELLVIE closes $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation as a new treatment modality

Cellvie

Cellvie Inc., a leader in Therapeutic Mitochondria Transplantation (TMT), an approach developed at Harvard Medical School, closes a $5.5 Million financing to get Series A-ready by the end of 2023.

$5.5M financing led by Taiho Ventures LLC, with participation of existing investors, including the Series Seed lead, Kizoo Technology Capital.

Read More

Kizoo invests in Rejuvenation Startup MoglingBio

MoglingBio

Berlin/Ulm, Germany – MoglingBio, a privately held biotech company, announces today that it has successfully completed its first seed investment round. Sole investor is venture capital firm Kizoo Technology Capital, a rejuvenation biotech investor focused on startups reversing age-related damage on a cellular and molecular level.

Read More

Rejuvenation Startup Summit premieres October, 14-15, 2022 in Berlin

Rejuvenation Startup Summit

The Forever Healthy Foundation is pleased to announce the world’s first Rejuvenation Startup Summit will be held October 14-15, 2022 in Berlin.

The Rejuvenation Startup Summit is a vibrant networking event for rejuvenation startups, longevity investors, and translational researchers, and aims to accelerate the development of the rejuvenation biotech industry.

Startups will be able to connect with investors in the longevity space, present their approach, and get them interested in their work. Investors can meet the most promising rejuvenation startups from all over the world and get in touch with them straight away. Researchers with a startup itch can learn how to successfully break out of the lab and found or join a rejuvenation startup.

The summit brings together all those working on therapies that aim to vastly extend the healthy human lifespan. In addition to an exciting range of keynotes speeches, presentations, and panels, the summit features an all-day startup forum for easy networking. Starting midday on Friday and finishing off on Saturday night with a big party, it offers ample opportunity to connect, learn and network with the most relevant players in the field.

The Rejuvenation Startup Summit is not only open to startups, investors, and translational scientists – all interested members of the broader longevity movement, scientists from related fields, aspiring students, and the general media are also welcome.

Learn more at: https://forever-healthy.org/summit

Read More

Kizoo Portfolio Company Elastrin Therapeutics Inc. closes $10M Funding Round

Matthias Breugelmans and Naren Vyavahare
Dr. Breugelmans and Prof. Dr. Vyavahare

Greenville, SC, U.S. – Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform to develop therapeutics that render calcified tissue and organs supple again, today announced the closing of a $10 million funding round led by Kizoo Technology Capital, a leading early-stage investor in breakthrough rejuvenation technologies. Other investors in the round include Starbloom Capital and SC Launch. Elastrin Therapeutics was founded in 2018 as a spin-out from Clemson University, where the technology was first developed over a 20-year period.

Read More

Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging

Aaron Cravens Portrait
Dr. Aaron Cravens

San Francisco, CA, U.S. – Revel Pharmaceuticals, a longevity therapeutics company developing enzymes to repair damage from aging, announced today that it has raised $8.4M in Seed financing. The oversubscribed round was led by Kizoo Technology Capital, a leading early-stage investor in breakthrough rejuvenation technologies, and Starbloom Capital with participation from Tubus LLC. The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic.

Read More

Kizoo Portfolio Company Staffbase Raises $115M at $1.1B Valuation to Achieve Global Leadership in Employee Communications Management

Banner Employee Communication Management

Chemnitz / Munich / New York – March 15, 2022 – Kizoo Portfolio Company Staffbase, a leading provider of employee communications management solutions, today announced a $115M (€106M) Series E financing round led by General Atlantic, a leading global growth equity firm. Staffbase will leverage the new funds to help scale internationally and strengthen its global leadership in the internal communications space. Existing investor Insight Partners also participated in the round.

Read More

Kizoo portfolio company LIfT BioSciences secures its largest financing to date with a further £5m

Hands forming a heart

London, UK ­– Kizoo portfolio company Biotech LIfT BioSciences today announced its largest financing round to date with a further £5m investment into the company in its mission to develop the first curative and affordable cell therapy for all solid tumours. The round was led by new investor Starbloom Capital with additional participation by Jonathan Milner, a leading biotech ‘super-angel’ investor and earlier stage investor in LIfT, Kizoo Technology Ventures, a leading early-stage investor in breakthrough rejuvenation technologies and Downing Ventures, a leading London-based investor.

Read More